ArticleDiagnostic and interventional imaging2020
Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab.
Article in Diagnostic and interventional imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- [Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia].Medicina clinica · 2020Pooled it
- Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review.International immunopharmacology · 2020Pooled it
- Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.Journal of medical virology · 2020Pooled it
- The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.Life sciences · 2020Pooled it
- Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab.Scientific reports · 2021Trial
- Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.The New England journal of medicine · 2021Trial
- Global Emergence of SARS-CoV2 Infection and Scientific Interventions to Contain its Spread.Current protein & peptide science · 2024Review
- Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine.International immunopharmacology · 2022Review
- Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity.Molecular biomedicine · 2022Review
- Pharmacological and non-pharmacological strategies in coronavirus disease 2019: A literature review.Annals of medicine and surgery (2012) · 2022Review
- Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 In Rheumatoid Arthritis Patients.Mediterranean journal of rheumatology · 2022Article
- Value and prognostic impact of a deep learning segmentation model of COVID-19 lung lesions on low-dose chest CT.Research in diagnostic and interventional imaging · 2022Article
- Secondary Infections in Patients with COVID-19 Pneumonia Treated with Tocilizumab Compared to Those Not Treated with Tocilizumab: A Retrospective Study at a Tertiary Hospital in Kenya.International journal of general medicine · 2022Article
- Targeting SARS-CoV-2 infection through CAR-T-like bispecific T cell engagers incorporating ACE2.Clinical & translational immunology · 2022Article
- Tocilizumab and COVID-19: Timing of Administration and Efficacy.Frontiers in pharmacology · 2022Review
- Natural Bioactive Molecules: An Alternative Approach to the Treatment and Control of COVID-19.International journal of molecular sciences · 2021Review
- Observational
- Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.Journal of medical virology · 2021Article
- The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.International journal of environmental research and public health · 2021Review
- Rationale for the use of sphingosine analogues in COVID-19 patients.Clinical medicine (London, England) · 2021Review
Corrections and comments
- Comment on
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.